Your Waterstones card is changing, introducing...
TELL ME MORE
Biologics 2000 - Comparability of Biotechnology Products: Washington, D.C., June 2000. - Developments in Biologicals 109 (Paperback)
  • Biologics 2000 - Comparability of Biotechnology Products: Washington, D.C., June 2000. - Developments in Biologicals 109 (Paperback)
zoom

Biologics 2000 - Comparability of Biotechnology Products: Washington, D.C., June 2000. - Developments in Biologicals 109 (Paperback)

(editor), (editor), (editor)
£68.20
Paperback 160 Pages / Published: 09/10/2002
  • We can order this

Usually despatched within 1 week

  • This item has been added to your basket
The globalization of research and development considering collaborative arrangements among companies for producing biotechnology-derived products often raises product comparability issues which are expected to increase in frequency and complexity. This volume reviews current scientific developments and regulatory issues relating to establishing comparability of biological products when manufactured within a single company or jointly among two or more companies (e.g. manufacturing changes, site changes). Recommendations for a framework constituting a harmonized document on comparability are also provided. A cadre of international regulatory and industry experts concluded and recommended that a) the unprecedented record of product safety enjoyed by the biotech industry is founded on the vigilance dedicated to process controls and product quality throughout the drug development continuum; b) intra-manufacturer process changes are in line with modern global practices, scientific and economic considerations; c) the innovators' proprietary development history, production experience, training, validated assays and standards constitute a solid basis for performing legitimate and scientifically rigorous comparisons of products when introducing manufacturing changes. Importantly, depending on the nature of the product, at times, comparisons may dictate expanded investigations in clinical trials; d) comparability, while robust in concept and application within one manufacturer's product, is not a surrogate for establishing inter-manufacturer therapeutic equivalence which is the foundation for `generic' products; e) an international harmonized approach guidance document is timely. Summarizing current thinking and practical experience, these proceedings should be read by academic, industry, and regulatory scientists who work with biological products prepared for use as vaccines, plasma derivatives, or therapeutic products.

Publisher: S Karger AG
ISBN: 9783805574273
Number of pages: 160
Weight: 320 g
Dimensions: 240 x 170 x 10 mm

You may also be interested in...

From Alchemy To Ipo
Added to basket
Modern Dictionary of Biotechnology
Added to basket
Biomaterials
Added to basket
£69.99
Paperback
Shuler
Added to basket
£103.99
Hardback
Genes, Cells and Brains
Added to basket
Natural Products Isolation
Added to basket
Starved for Science
Added to basket
From Genes to Genomes
Added to basket
Bacterial Disease Mechanisms
Added to basket
Gene Cloning
Added to basket
£47.99
Paperback
Bionanotechnology II
Added to basket
Genetics
Added to basket
£9.99
Paperback

Reviews

Please sign in to write a review

Your review has been submitted successfully.